REPLIMUNE GROUP, INC. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
REPLIMUNE GROUP, INC. (REPL) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $300.00 thousand for the 12-month period ending 2023-03-31, per its 10-Q filed 2023-08-03.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2023-11-07
- REPLIMUNE GROUP, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2022-12-31 was $300.00K.
- REPLIMUNE GROUP, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2022-09-30 was $300.00K.
- REPLIMUNE GROUP, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2020-12-31 was $13.78M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month as first filed | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|---|---|
| 2023-03-31 | $300.00K 10-Q · filed 2023-08-03 | |||
| 2022-12-31 | $300.00K 10-Q · filed 2023-02-09 | $600.00K derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-09-30 | $300.00K 10-Q · filed 2023-11-07 | $200.00K 10-Q · filed 2022-11-03 | $300.00K 10-Q · filed 2023-11-07 | |
| 2020-12-31 | $13.78M 10-Q · filed 2022-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |